Lukas Junk, Volker M Schmiedel, Somraj Guha, Katharina Fischel, Peter Greb, Kristin Vill, Violetta Krisilia, Lasse van Geelen, Klaus Rumpel, Parvinder Kaur, Ramya V Krishnamurthy, Shridhar Narayanan, Radha Krishan Shandil, Mayas Singh, Christiane Kofink, Andreas Mantoulidis, Philipp Biber, Gerhard Gmaschitz, Uli Kazmaier, Anton Meinhart, Julia Leodolter, David Hoi, Sabryna Junker, Francesca Ester Morreale, Tim Clausen, Rainer Kalscheuer, Harald Weinstabl, Guido Boehmelt
Antimicrobial resistance is a global health threat that requires the development of new treatment concepts. These should not only overcome existing resistance but be designed to slow down the emergence of new resistance mechanisms. Targeted protein degradation, whereby a drug redirects cellular proteolytic machinery towards degrading a specific target, is an emerging concept in drug discovery. We are extending this concept by developing proteolysis targeting chimeras active in bacteria (BacPROTACs) that bind to ClpC1, a component of the mycobacterial protein degradation machinery...
March 5, 2024: Nature Communications